Stock comparison
Galapagos N.V.
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GLPG
Galapagos N.V.
Market cap
$1.81B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GLPG | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 41D | 65C | GMAB |
| Benjamin Graham | 28F | 64C | GMAB |
| Philip Fisher | 56C | 48D | GLPG |
| Peter Lynch | 76B | 25F | GLPG |
| Joel Greenblatt | 39D | 76B | GMAB |
| Charlie Munger | 46D | 68C | GMAB |
| Terry Smith | 46D | 71C | GMAB |
Side-by-side metrics
| Metric | GLPG | GMAB |
|---|---|---|
| Market cap | $1.81B | $16.5B |
| P/E (TTM) | 3.1x | 6.2x |
| EV/EBIT | 2.9x | 12.0x |
| ROIC (TTM) | 17.67% | 43.78% |
| Gross margin | 98.01% | 93.88% |
| Net margin | 46.83% | 18.23% |
| Revenue CAGR 5y | 23.07% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GLPG leads on
- Revenue CAGR 5y23.07%vs -18.45%+180%
- Debt / Equity0.0xvs 0.1x+97%
- EV/EBIT2.9xvs 12.0x+76%
- Net margin46.83%vs 18.23%+61%
GMAB leads on
- Market cap$16.5Bvs $1.81B+89%
- ROIC (TTM)43.78%vs 17.67%+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.